SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

There is emerging evidence of multiple benefits for a range of clinical indications in patients without type 2 diabetes. This review will describe and compare the evidence around the SGLT2 inhibitors and GLP-1 receptor agonists individually and in combination.

Source:

The Lancet